

- Glucocorticoid(s) (*Cont.*):
 for episcleritis and scleritis, 200
 equipotency, 2326
 for fatigue, 63
 for fever, 126
 for fever of unknown origin, 141
 genomics of response to, 775
 for giant cell arteritis, 2189
 for gout, 2234
 for Graves' ophthalmopathy, 2297
 half-lives of, 400e-2
 for hypercalcemia, 314, 610, 2480t, 2481
 for hyperesinophilic syndromes, 423, 1686
 for IBD, 1960
 for idiopathic cutaneous vasculitis, 2192
 for IgA vasculitis, 2190
 for immune thrombocytopenic purpura, 728
 for immunosuppression, 1828, 1829t
 for inflammatory myopathies, 2200–2201
 inhaled
 actions of, 1677, 1678f
 adverse effects of, 1677, 1705
 for asthma, 1677, 1678f
 for COPD, 1705
 for cough, 245
 intraarticular, for osteoarthritis, 2232, 2232t
 intralesional
 for alopecia areata, 355t
 for mucous membrane pemphigoid, 374
 for pemphigus foliaceus, 372
 intranasal
 adverse effects of, 2122
 for allergic rhinitis, 2122, 2123f
 for sinusitis, 216, 227, 228
 for nausea and vomiting, 62, 260t
 for neck pain, 123
 for optic neuritis, 202
 for orbital pseudotumor, 207
 for otitis externa, 228
 for pain, 61
 for parainfluenza virus infection, 1208
 resistance to, 1680, 2318t
 for rheumatic fever, 2153
 for rheumatoid arthritis, 2145
 for Sweet syndrome, 487
 synthesis of, 2309, 2309f, 2355f
 systemic
 adverse effects of, 1677–1678, 1706, 2130t, 2132, 2182t
 for asthma, 1677–1678
 for atopic dermatitis, 345
 for bullous pemphigoid, 372
 for cerebral edema, 598
 for COPD exacerbation, 1707
 for drug-induced hypersensitivity syndrome, 382
 for drug-induced urticaria/angioedema, 381
 drug interactions of, 2130t
 for Duchenne's muscular dystrophy, 462e-8
 for epidermolysis bullosa acquisita, 374
 for erythema nodosum leprosum, 1128
 for hypercalcemia, 314
 for IgG4-related disease, 391e-3
 for interstitial lung diseases, 1711
 for lichen simplex chronicus, 345
 for lupus nephritis, 1838
 for Ménière's disease, 219
 for minimal change disease, 1842
 for MS, 2667
 for myasthenia gravis, 2705
 for neuromyelitis optica, 2673
 for pemphigoid gestationis, 373
 for pemphigus foliaceus, 372
 for pemphigus vulgaris, 371
 for phototoxicity, 390
 for sarcoidosis, 2210–2211, 2212t
 for serum sickness, 2737
 for sinusitis, 214
 for SJS or TEN, 383
 for SLE, 2130t, 2132
 for subacute cutaneous lupus erythematosus, 375
 for systemic mastocytosis, 2121
 for systemic sclerosis, 2164–2165
 for Takayasu's arteritis, 2190
 for thrombotic thrombocytopenic purpura, 730
 topical
 adverse effects of, 381, 2130t
 for atopic dermatitis, 345
 for bullous pemphigoid, 372
 for candidiasis, 351
 for contact dermatitis, 345
 for dermatitis, 354t
 for dermatomyositis, 375
 for hand eczema, 346
 for herpes simplex keratitis, 200
 for lichen planus, 349
 for lichen simplex chronicus, 345
 for morbilliform drug eruption, 381
 for mucous membrane pemphigoid, 374
 for pemphigoid gestationis, 373
 for pemphigus foliaceus, 372
 for phototoxicity, 390
 for pityriasis rosea, 349
 for psoriasis, 348, 354t
 for seborrheic dermatitis, 347
 for SLE, 2130t
 for stasis dermatitis, 346
 for sulfur mustard exposure, 262e-4
 for uveitis, 200
 for vitiligo, 358t
 for tuberculous meningitis, 775
 for urticaria, 2119–2120
 for vasculitis, 2181–2182
 withdrawal from, 103e-15, 378
 Glucocorticoid receptor gene mutations, 2356t
 Glucocorticoid-remediable aldosteronism (GRA;
 familial hyperaldosteronism type I)
 clinical features of, 1619, 1620t
 complications of, 2319
 diagnosis of, 307, 1619
 genetic considerations in, 307, 434, 1620t, 2318–2319, 2318t
 treatment of, 1619, 2320
 Gluconogenesis, 95e-1, 461, 2430
 Glucosamine, 2232
 Glucose
 in ascitic fluid, 287–288
 balance and counterregulation of, 2430, 2431f
 for hyperkalemia, 312
 metabolism in cancer cells, 102e-12
 plasma levels of, 2401, 2401f, 2401t, 2760t
 regulation of, 2399f, 2401, 2402–2403, 2402f
 renal transport of, 332e-3f, 332e-8
 in specialized nutritional support formulas, 98e-4–5, 98e-7
 Glucose-6-phosphatase deficiency (type Ia GSD;
 Von Gierke's disease), 375e-1, 433e-1, 433e-2t, 433e-3
 Glucose-6-phosphate dehydrogenase (G6PD)
 deficiency, 654
 clinical features of, 393, 655–656
 diagnosis of, 656, 656f, 2755t
 drug contraindications in, 656, 656t
 dapson, 1126, 1262
 furazolidone, 246e-9
 primaquine, 246e-12, 1378t, 1380t, 1381, 1384
 rasburicase, 1795
 drug responses in, 39t, 40
 early interventions for, 450t
 epidemiology of, 393, 655, 655f
 genetic considerations in, 654t, 655
 genetic testing for, 450t
 global considerations in, 655, 655f
 jaundice in, 281
 malaria resistance and, 656, 1371
 pathophysiology of, 650f, 654–655, 654f
 red cell enzyme abnormalities in, 654t
 Rocky Mountain spotted fever in, 1156
 treatment of, 656–657
 Glucose-6-phosphate isomerase, 372e-24t
 Glucose-6-phosphate isomerase (GPI)
 deficiency, 650f, 654t
 Glucose–galactose, malabsorption of, 435e-1t
 Glucose tolerance, 2401, 2401t, 2451, 2454
 Glucose-transport defect, 435e-1t
 Glucose transporter 1 (GLUT-1), 225e-3, 247
 Glucose transporter 2 (GLUT-2), 247
 Glucose transporter 2 (GLUT-2) deficiency
 (Fanconi-Bickel syndrome; type XI
 GSD), 332e-7t, 433e-2t, 435e-1t, 2434–2435
 Glucose transporter 9 (GLUT9), 431e-1, 431e-2f, 431e-3
 α-Glucosidase inhibitors, 2414t, 2415, 2416
 Glue sniffer's neuropathy, 2688t, 2689
 GLUR (glutamate receptor), 372e-24t
 GLUT9 (glucose transporter 9), 431e-1, 431e-2f, 431e-3
 Glutamate, 88, 444e-3t
 Glutamate decarboxylase (GAD65), 372e-24t
 Glutamate receptor (GLUR), 372e-24t
 Glutamine metabolism disorders, 434e-3t
 Glutamine synthase deficiency, 434e-3t
 γ-Glutamylcarboxylase, 736, 736f
 Glutaric acidemia, 434e-3t
 Glutathione peroxidase deficiency, 657
 Glutathione-S-transferase proteins, 280
 Glutathione synthase deficiency, 654t
 Gluten-free diet
 for ataxic disorders, 2630
 for celiac disease, 1942
 for dermatitis herpetiformis, 373
 Gluten-induced enteropathy. *See* Celiac disease (gluten-induced enteropathy)
 Gluten intolerance, nonceliac, 269
 Glutethimide, 41, 42t, 473e-11t
 Glyburide, 48, 727t, 2414t
 Glycan shield, 1244
 Glycemic control
 in critically ill patient, 1734
 in diabetes mellitus, 2409–2410
 in diabetic nephropathy, 2425–2426
 diabetic retinopathy and, 2423f
 long-term, assessment of, 2410
 in metabolic syndrome, 291e-7, 2454
 perioperative, 55
 in pregnancy, 48
 in sepsis/septic shock, 1758
 Glycereraldehyde-3-phosphate dehydrogenase
 (GAPD) deficiency, 654t
 Glycine, 444e-3t
 Glycine encephalopathy, 434e-2t
 Glycine metabolism disorders, 434e-2t
 Glycine N-methyltransferase deficiency, 434e-2t
 Glycine receptor antibodies, 614t, 617
 Glycogen, 433e-1
 Glycogenesis Ib disease, 375e-1
 Glycogenolysis, myocardial, 265e-10
 Glycogen storage diseases (GSD), **433e-1**
 clinical features of, 433e-2–3t, 2198, 2434–2435
 global considerations in, 433e-5
 with hepatomegaly and hypoglycemia
 type 0, 433e-2t
 type Ia (von Gierke's disease), 432e-2t, 433e-1, 433e-3, 436e-5f
 type Ib, 432e-2t, 433e-3
 type III, 432e-2t, 433e-3, 436e-6f, 462e-14, 1565
 type VI (Hers disease), 433e-2t, 433e-4
 type IX, 332e-7t, 432e-2t, 433e-4, 462e-14
 type X, 462e-14
 type XI (Fanconi-Bickel syndrome), 332e-7t, 433e-2t, 433e-4, 462e-14
 hyperuricemia in, 431e-2
 IBD and, 1949t
 late-onset, 432e-4t
 with liver cirrhosis (type IV), 433e-2t, 462e-14
 with muscle-energy impairment
 β-enolase deficiency, 432e-2t, 462e-14
 lactate dehydrogenase deficiency, 432e-2t, 462e-14
 pyruvate kinase deficiency, 281, 433e-2t, 650f, 653–654, 654t
 type V (McCardle's disease), 433e-2t, 433e-4, 462e-14
 type VII (Tarui's disease), 433e-2t, 462e-14, 654t
 type X, 433e-2t, 462e-14